Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae?

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 4, 2017, Pages

  Marshall, Steven ^a   Hujer, Andrea M ^a,b   Rojas, Laura J ^a,b   Papp Wallace, Krisztina M ^a   Humphries, Romney M ^c   Spellberg, Brad ^d   Hujer, Kristine M ^a,b   Marshall, Emma K ^a   Rudin, Susan D ^a,b   Perez, Federico ^a,b   Wilson, Brigid M ^a   Wasserman, Ronald B ^e   Chikowski, Linda ^f   Paterson, David L ^g   Vila, Alejandro J ^h   Van Duin, David ⁱ   Kreiswirth, Barry N ^j   Chambers, Henry F ^k   Fowler, Vance G ^l   Jacobs, Michael R ^b   Pulse, Mark E ^m   Weiss, William J ^m   Bonomo, Robert A ^a,b   more..

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LAC USC MEDICAL CENTER   (United States)

^e Infectious Disease Doctors Medical Group   (United States)

^f John Muir Health   (United States)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

^m UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

more..

Author keywords

Avibactam; Aztreonam; Ceftazidime; Disk diffusion; Metallo lactamases

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; BETA LACTAMASE IMP; BETA LACTAMASE NDM; BETA LACTAMASE OXA 48; CEFTAZIDIME; METALLO BETA LACTAMASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; CYCLOPHOSPHAMIDE;

AGAR DILUTION; ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DISK DIFFUSION; DRUG EFFICACY; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; FEMALE; IN VIVO STUDY; INHIBITION ZONE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BACTERIAL COUNT; CHEMICALLY INDUCED; CHEMISTRY; COMBINATION DRUG THERAPY; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PLASMID; SOFT TISSUE INFECTIONS; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; AZTREONAM; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEFTAZIDIME; COLONY COUNT, MICROBIAL; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; GENE EXPRESSION; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PLASMIDS; SOFT TISSUE INFECTIONS; THIGH;

EID: 85016960515     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02243-16     Document Type: Article

References (17)

1. Centers for Disease Control and Prevention. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 62:165-170.
2. van Duin D, Bonomo RA. 2016. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation beta-lactam/beta-lactamase inhibitor combinations. Clin Infect Dis 63:234-241. https://doi.org/10.1093/cid/ciw243.
3. Falcone M, Paterson D. 2016. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother 71:2713-2722. https://doi.org/10.1093/jac/dkw239.
4. Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 59:6605-6607. https://doi.org/10.1128/AAC.01165-15.
5. Pages JM, Peslier S, Keating TA, Lavigne JP, Nichols WW. 2015. The role of the outer membrane and porins in the susceptibility of beta-lactamase-producing Enterobacteriaceae to ceftazidimeavibactam. Antimicrob Agents Chemother 60:1349-1359. https://doi.org/10.1128/AAC.01585-15.
6. Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. 2015. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of betalactamase-producing strains. Antimicrob Agents Chemother 59:3509-3517. https://doi.org/10.1128/AAC.00163-15.
7. Epstein L, Hunter JC, Arwady MA, Tsai V, Stein L, Gribogiannis M, Frias M, Guh AY, Laufer AS, Black S, Pacilli M, Moulton-Meissner H, Rasheed JK, Avillan JJ, Kitchel B, Limbago BM, MacCannell D, Lonsway D, Noble-Wang J, Conway J, Conover C, Vernon M, Kallen AJ. 2014. New Delhi metallo-beta-lactamase-producing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes. JAMA 312:1447-1455. https://doi.org/10.1001/jama.2014.12720.
8. Lascols C, Hackel M, Marshall SH, Hujer AM, Bouchillon S, Badal R, Hoban D, Bonomo RA. 2011. Increasing prevalence and dissemination of NDM-1 metallo-beta-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother 66:1992-1997. https://doi.org/10.1093/jac/dkr240.
9. CLSI. 2015. Performance standards for antimicrobial susceptibility testing, 25th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Drawz SM, Papp-Wallace KM, Bonomo RA. 2014. New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835-1846. https://doi.org/10.1128/AAC.00826-13.
11. Alm RA, Johnstone MR, Lahiri SD. 2015. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J Antimicrob Chemother 70:1420-1428. https://doi.org/10.1093/jac/dku568.
12. Asli A, Brouillette E, Krause KM, Nichols WW, Malouin F. 2016. Distinctive binding of avibactam to penicillin-binding proteins of Gram-negative and Gram-positive bacteria. Antimicrob Agents Chemother 60:752-756. https://doi.org/10.1128/AAC.02102-15.
13. King AM, King DT, French S, Brouillette E, Asli A, Alexander JA, Vuckovic M, Maiti SN, Parr TR, Jr, Brown ED, Malouin F, Strynadka NC, Wright GD. 2016. Structural and kinetic characterization of diazabicyclooctanes as dual inhibitors of both serine-beta-lactamases and penicillin-binding proteins. ACS Chem Biol 11:864-868. https://doi.org/10.1021/acschembio.5b00944.
14. Rahme C, Butterfield JM, Nicasio AM, Lodise TP. 2014. Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit? Diagn Microbiol Infect Dis 80:239-259. https://doi.org/10.1016/j.diagmicrobio.2014.07.007.
15. Mojica MF, Ouellette CP, Leber A, Becknell MB, Ardura MI, Perez F, Shimamura M, Bonomo RA, Aitken SL, Shelburne SA. 2016. Successful treatment of bloodstream infection due to metallo-beta-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient. Antimicrob Agents Chemother 60:5130-5134. https://doi.org/10.1128/AAC.00264-16.
16. Keepers TR, Gomez M, Celeri C, Nichols WW, Krause KM. 2014. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 58:5297-5305. https://doi.org/10.1128/AAC.02894-14.
17. Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. 2011. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 55:82-85. https://doi.org/10.1128/AAC.01198-10.